Article

Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders

2023-01-14

Abstract excerpt

Current approved COVID-19 vaccines, notably mRNA and adenoviral vectored technologies, still fail to fully protect against infection and transmission of various SARS-CoV-2 variants. The mucosal immunity at the upper respiratory tract represents the first line of defense against respiratory viruses such as SARS-CoV-2 and is thus critical to develop vaccine blocking human-to-human transmission. We measured systemic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7a34a3b4-c056-5326-892e-4e9ba94a6060
DOI: 10.1101/2023.01.13.23284341

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disordersDOI 10.1101/2023.01.13.23284341Read

Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19Semantic proximity Read

SARS-CoV-2 oral tablet vaccination induces neutralizing mucosal IgA in a phase 1 open label trialSemantic proximity Read

Detection of anti–SARS-CoV-2 mucosal IgA in clinical saliva samples after a dose of Novavax COVID-19 vaccineSemantic proximity Read

Immunoglobulin a Response to Sars-Cov-2 Infection and ImmunitySemantic proximity Read

Utility of nasal swabs for assessing mucosal immune responses towards SARS-CoV-2Semantic proximity Read

COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in salivaSemantic proximity Read

SARS-CoV-2-Specific Immune Responses in Vaccination and Infection during the Pandemic in 2020–2022Semantic proximity Read

Phase 1 Study of Safety, Reactogenicity, and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized AdultsSemantic proximity Read

A Rapid Saliva Test for Monitoring Immune Protection against SARS -CoV-2 and its VariantsSemantic proximity Read

Nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccinationSemantic proximity Read

Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variantsSemantic proximity Read

Subclinical SARS-CoV-2 Infections and Endemic Human Coronavirus Immunity Shape SARS-CoV-2 Saliva Antibody ResponsesSemantic proximity Read